SATELLOS Announces Proposed Non-Brokered Offerings Of Unsecured Non-Convertible Debentures of up to $2.25 Million
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
SATELLOS to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos’
SATELLOS Announces Further Preclinical Progress with Development Candidate
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 as a Potential Treatment for Duchenne
SATELLOS Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
Satellos Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
SATELLOS Announces Development Candidate
- SAT-3153 Designated for pre-IND Studies - TORONTO, January 03, 2023 – Satellos Bioscience Inc.
SATELLOS Announces Q3 2022 Financial Results and Operational Highlights
SATELLOS BIOSCIENCE ANNOUNCES Q3 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS TORONTO, November 23, 2022 –
SATELLOS Announces Advancement of Compounds to Next Stage of Development
-Proof of concept studies to be completed by YE- TORONTO, November 03, 2022 – Satellos
SATELLOS to present preliminary preclinical proof of concept data for an additional rare disease at World Muscle Society Meeting
Satellos Bioscience Inc. to present preliminary preclinical proof of concept data for an additional rare
SATELLOS INC. Announces Licensing of Formulation Technology and Expand Collaboration with NW PHARMATECH LTD.
TORONTO, October 6, 2022 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), is
SATELLOS Announces OTCQB Listing in the United States
SATELLOS BIOSCIENCE ANNOUNCES OTCQB LISTING IN THE UNITED STATES TORONTO, October 6, 2022 – Satellos